Drug profile

The FDA adverse-event record for Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture

153 FDA reports name Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#622 of 2,679
by report volume (all drugs)
153
adverse-event reports
7.2%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture ranks #621 of 2679 by total reports (153) and #684 of 1130 by death-coded share (7.2%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#621
This drug, reports of 2679
#684
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture has 153 reports now versus 153 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture changes

Signature read: 153 reports place Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture in the upper third of FDA AER volume (#622 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
153
Total Reports
11
Deaths Reported
7.2%
Death-coded share of reports

Active Ingredients

Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture

Administration Routes

NasalUnknownSubcutaneousOralOtherParenteral

Species Affected

Dog 153

Most Affected Breeds

Retriever - Labrador 17
Terrier - Yorkshire 12
Retriever - Golden 9
Chihuahua 7
Shih Tzu 6
Pit Bull 5
Boxer (German Boxer) 5
Bulldog - French 5
Siberian Husky 5
Crossbred Canine/dog 4

Most Reported Reactions

Vomiting 34
Lethargy (see also Central nervous system depression in 'Neurological') 24
Lack of efficacy - NOS 20
Diarrhoea 20
Cough 19
Other abnormal test result NOS 17
Anaphylaxis 13
Death 10
Pale mucous membrane 9
Lack of efficacy (virus NOS) 9
Lethargy (see also Central nervous system depression in Neurological) 9
Anorexia 8

Outcome Breakdown

Outcome Unknown
73 (47.7%)
Recovered/Normal
37 (24.2%)
Ongoing
32 (20.9%)
Died
11 (7.2%)

Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture: high report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

What to do with this drug

  • Compare Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture's report volume and death-coded share against similar drugs nationwide. See similar drugs
  • Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
  • Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture (#622 of 2,679 by report volume); death-coded 7.2%. PlainBreed drug row · report volume stamp 153 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →